Haleon (NYSE:HLN) Stock Gets Downgrade from Zacks Research

Haleon (NYSE:HLN) was downgraded by research analysts at Zacks Research from a “hold” rating to a “strong sell” rating in a report issued on Thursday, Zacks reports.

A number of other equities analysts have also recently issued reports on HLN. Wall Street Zen cut shares of Haleon from a “buy” rating to a “hold” rating in a research report on Saturday, October 3rd. Morgan Stanley restated an “overweight” rating on shares of Haleon in a research report on Thursday, August 6th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Haleon in a research note on Friday, September 25th. Berenberg Bank reaffirmed a “buy” rating on shares of Haleon in a research note on Wednesday, August 5th. Finally, Deutsche Bank Aktiengesellschaft reiterated a “sell” rating on shares of Haleon in a report on Wednesday, September 9th. Two equities research analysts have rated the stock with a Strong Buy rating, three have issued a Buy rating, three have given a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $4.90.

Haleon Stock Down 0.8%

HLN stock opened at $10.29 on Thursday. The firm has a 50-day moving average price of $9.56 and a 200-day moving average price of $9.51. Haleon has a 12 month low of $8.65 and a 12 month high of $11.28. The company has a current ratio of 0.69, a quick ratio of 0.52 and a debt-to-equity ratio of 0.38. The stock has a market capitalization of $45.30 billion, a P/E ratio of 26.37, a price-to-earnings-growth ratio of 2.34 and a beta of 0.14.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. Root Financial Partners LLC acquired a new stake in Haleon during the 3rd quarter worth approximately $25,000. Western Wealth Management LLC bought a new position in Haleon during the 1st quarter worth $29,000. Annis Gardner Whiting Capital Advisors LLC raised its position in shares of Haleon by 402.0% during the first quarter. Annis Gardner Whiting Capital Advisors LLC now owns 3,002 shares of the company’s stock worth $30,000 after acquiring an additional 2,404 shares during the last quarter. Parkside Financial Bank & Trust lifted its position in shares of Haleon by 20.4% in the 2nd quarter. Parkside Financial Bank & Trust now owns 6,233 shares of the company’s stock worth $58,000 after purchasing an additional 1,055 shares during the period. Finally, Gryphon Financial Partners LLC acquired a new position in Haleon in the first quarter valued at $101,000. Institutional investors own 6.67% of the company’s stock.

Haleon Company Profile

Haleon plc (NYSE: HLN) is a global consumer health company that develops, manufactures and markets over-the-counter medicines, oral health products, vitamins and supplements. Its portfolio is organized around categories including pain relief, respiratory health, digestive health, therapeutic oral care, everyday oral care, vitamins and minerals, and skin health.

Haleon’s well-known brands include Sensodyne, Polident, parodontax, Centrum, Advil, Voltaren, Panadol, Otrivin and Theraflu. The company’s products are sold through pharmacies, supermarkets, retailers and e-commerce channels, serving consumers in markets around the world.

Haleon was established as an independent consumer health business following its demerger from GSK in July 2022.